Clinical Trials Browser

Completed × BID protein, human × Other hematologic neoplasm × Clear all

NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Phase 3 Completed

199 enrolled 13 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01856283 2021-01-13

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase